Drug Profile
Pramlintide biosimilar - Paras Biopharmaceuticals
Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Paras Biopharmaceuticals Finland
- Class Antihyperglycaemics; Macromolecular substances; Proteins
- Mechanism of Action Islet amyloid polypeptide stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 28 Jun 2019 No recent reports of development identified for research development in Diabetes-mellitus in Finland (Parenteral)
- 20 May 2015 Early research in Diabetes mellitus in Finland (Parenteral) (Paras pipeline, May 2015)